We first validated the on-target gene editing effects of Brd9&Jmjd6 and Kat6a&Jmjd6 dual-crRNAs in RN2c12 and B16-F10c12 melanoma cells (Supplementary Fig. 16). The gene discussed is KAT6A; the disease is melanoma.